Literature DB >> 2828461

Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis.

H C Hsu1, M Z Wu, M H Chang, I J Su, D S Chen.   

Abstract

To elucidate the etiologic role of chronic hepatitis B virus (HBV) infection and the role of liver cirrhosis in hepatocellular carcinoma (HCC), pathologic and virologic features of the disease were studied in 51 children with HCC; these accounted for 4.3% of 1195 pathologically proven HCC patients examined in the last three decades. Males predominated (M/F = 3.3:1), and the mean age was 11 years (range: 4-15 years). Hepatitis B surface antigen (HBsAg) was detected in the liver and/or serum of 100% of 42 children by immunocytochemical and/or radioimmunoassay, in the serum of 90% of 10 siblings, and more importantly in 94.1% of 17 mothers, suggesting that infection from familial HBsAg carriers, particularly carrier mothers, may contribute to the high incidence. Liver cirrhosis was frequent (74%), especially in the unresectable cases (87%); in the 20 children under 9 years of age, 95% were cirrhotic, a significantly higher level than the 58% of the 26 older children, P less than 0.005. All but one had advanced HCC, with 1-year survival in only 10.5%. The advanced HCC coupled with young age suggests that HCC can develop rapidly. The low positive rates of serum hepatitis B e antigen (HBeAg, 18%) and liver hepatitis B core antigen (11%) coupled with high frequency of liver cirrhosis indicate that an early HBeAg seroconversion to anti-HBe, in association with severe liver injury, may play an important role in the rapid development of HCC in children.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828461     DOI: 10.1016/s0168-8278(87)80030-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  18 in total

1.  Chronic type B hepatitis and primary hepatocellular carcinoma in children.

Authors:  C Crivellaro; P Cadrobbi; G Perilongo; F Rossetti; P Pontisso; F Bortolotti
Journal:  Eur J Pediatr       Date:  1991-07       Impact factor: 3.183

2.  Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.

Authors:  J Petersen; M Dandri; A Bürkle; L Zhang; C E Rogler
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 3.  Viral hepatitis.

Authors:  G V Gregorio; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

4.  Natural history and clinical management of chronic hepatitis B virus infection in children.

Authors:  Mei-Hwei Chang
Journal:  Hepatol Int       Date:  2008-03-06       Impact factor: 6.047

5.  Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents.

Authors:  Xu-Feng Zhang; Xue-Min Liu; Tao Wei; Chang Liu; Mu-Xing Li; Zhi-Da Long; Yi Lv
Journal:  Pediatr Surg Int       Date:  2013-06-22       Impact factor: 1.827

6.  Virchows node: rare presentation of childhood hepatocellular carcinoma.

Authors:  R K Mondal; A Dutta; K Basu; S Chakraborti
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

Review 7.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 8.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

9.  Interferon alfa-2b therapy in children with chronic hepatitis B.

Authors:  E M Sokal; S Wirth; P Goyens; A Depreterre; C Cornu
Journal:  Gut       Date:  1993       Impact factor: 23.059

10.  Children with Chronic Hepatitis B in the United States and Canada.

Authors:  Kathleen B Schwarz; Yona Keich Cloonan; Simon C Ling; Karen F Murray; Norberto Rodriguez-Baez; Sarah Jane Schwarzenberg; Jeffrey Teckman; Lilia Ganova-Raeva; Philip Rosenthal
Journal:  J Pediatr       Date:  2015-09-10       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.